SOUTH SAN FRANCISCO, Calif.--Axys Pharmaceuticals and Signal Pharmaceuticals announced they have entered into a collaboration for the accelerated discovery of compounds that interact with specific cell signaling pathways. Signal will use its proprietary assays to screen small molecules derived from Axys's compound libraries. Specific molecular targets were not disclosed.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.